Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06184841
Status:
COMPLETED
Last Update Posted:
2023-12-28
First Post:
2023-01-03
Brief Title:
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
Hepatic Arterial Infusion Chemotherapy Combined Sintilimab for Predominant Liver Metastasis From Esophageal Squamous Cell Carcinoma- A Pilot Study
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with liver metastasis from esophagus squamous ESC are usually offered systemic therapy However for those with predominant liver disease or failure of system therapy local liver management becomes an option This prospective single center study aimed to evaluate the efficacy and adverse events of hepatic arterial infusion chemotherapy HAIC using percutaneous catheter placement techniques for liver metastases from esophagus squamous ESC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None